Per Migliorare la Guarigione di Pazienti Affetti da Infezione del Tratto Respiratorio

BIBLIOGRAFIA

• Cockburn IM, Bailit HL, Berndt ER, et al. Loss of work productivity due to illness and medical treatment. J Occup Environ Med 1999; 41: 948–53.
   PubMed Web of Science ®Google Scholar
• Intercontinental Medical Statistics, Plymouth Meeting, PA. 1999.
   Google Scholar
• Guillemot D, Carbon C, Balkau B, et al. Low dosage and long treatment duration of beta-lactams: risk factors for carriage of penicillin-resistant S. pneumoniae. JAMA 1998; 279: 365–70.
   Web of Science ®Google Scholar
• Hoffken G. Epidemiology of respiratory tract infection. Eur Respir Rev 2000; 10: 149–55.
   Google Scholar
• Reinert RR, Simic S, Al-Lahham A, et al. Antimicrobial resistance of S. pneumoniae recovered from outpatients with respiratory tract infections in Germany from 1998-1999: results of a national surveillance study. J Clin Microbiol 2001; 39: 1187–9.
   Google Scholar
• Blondeau J. Expanded activity and utility of the new flu-oroquinolones: a review. Clin Ther 1999; 21: 3–40.
   PubMed Web of Science ®Google Scholar
• Sonam A, Honeybourne D, Andrews J, et al. Concentration of moxifloxacin in serum and pulmonary com-partments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 1999; 44: 835–8.
   PubMed Web of Science ®Google Scholar
• Niederman MS, McCombs JS, Unger AN. Treatment costs of acute exacerbations of chronic bronchitis. Clin Ther 1999; 21: 576–91.
   PubMed Web of Science ®Google Scholar
• Statistisches Bundesamt. Gesundheitsbericht fur Deutschland 1998: 234-6.
   Google Scholar
• Bartlett JG. Management of Respiratory Tract Infections. 1” Ed. Williams & Wilkins, 1997: 1–117.
   Google Scholar
• Wilson R, Kubin R, Ballin I, et al. Five day moxi-floxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbation of chronic bronchitis. J Antimicrob Chemother 1999; 44; 501–13.
   PubMed Web of Science ®Google Scholar
• Chodosh S, DeAbate A, Haversotck D, et al. Short course moxifloxacin therapy for treatment of acute exacerba-tions of chronic bronchitis. Resp Med 2000; 94: 18–27.
   PubMed Web of Science ®Google Scholar
• Schaberg T, Ballin I, Huchon G, et al. A multinational, multicentre, non-blinded randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis. J Int Med Res 2001; 29: 314–28.
   PubMed Web of Science ®Google Scholar
• DeAbate CA, Mathew CP, Warner JH et al. The safety and efficacy of short-course moxifloxacin vs azithromycin in the treatment of patients with acute axacerbation of chronic bronchitis. Resp Med 2000; 94: 1029–37.
   PubMed Web of Science ®Google Scholar
• Kreis S, Herrera N, Golzar N, et al. A comparison of moxifloxacin and azithromycin in the treatment of acute exac-erbations of chronic bronchitis J Clin Out Mgmt 2000, 7; 33–41.
   Google Scholar
• Urueta J, Ariza J, De Brito A, et al. Safety and effica-cy of moxifloxacin vs levofloxacin in the treatment of AECB. Clin Microbiol Infect 2001; 7 (suppl 1): 168 (abstract).
   Google Scholar
• Hautamaki D, Bruya T, Kureishi A, et al. Short course (5 day) moxifloxacin versus 7-day levofloxacin therapy for treatment of acute exacerbations of chronic bronchitis. Today's Therapeut Trends, 2001; 19 (2): 117–36.
   Google Scholar
• Landen H, Moller M, Tillotson G, et al. Clinical experi-ence in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone moxi-floxacin. J Int Med Res 2001; 29: 51–60.
   PubMed Web of Science ®Google Scholar
• Lorenz J, Busch W, Thate-Waschke I-M, et al. Moxifloxacin in acute exacerbations of chronic bronchitis: Clinical evaluation and assessment by patients. J Int Med Res 2001; 29: 61–73.
   PubMed Web of Science ®Google Scholar
• Lorenz J, Thate-Waschke I-M, Mast O, et al. Treat-ment outcomes in acute exacerbations of chronic bronchitis: comparison of macrolides and moxifloxacin from the patient perspective. J Int Med Res 2001; 29: 74–86.
   PubMed Web of Science ®Google Scholar
• Miravittles M, Ros F, Cobos A, et al. The efficacy of moxifloxacin in acute exacerbations of chronic bronchitis: A Spanish physician and patient perspective. Int J Clin Pract 2001; 55: 437–41.
   PubMed Web of Science ®Google Scholar
• United States Department of Health and Human Services. National health survey. Prevalence of selected chron-ic conditions. United States, 1983-85. Hyattsville, MD.US Department of Health and Human Services, 1987.
   Google Scholar
• Kankam CG, Sallis R. Acute sinusitis in adults. Difficult to diagnose, essential to treat. Postgrad Med 1997; 102: 252–8.
   Google Scholar
• Gwaltney JM. Acute community-acquired sinusitis. Clin Infect Dis 1996; 23: 1209–25.
   PubMed Web of Science ®Google Scholar
• Poole MD. Antimicrobial therapy for sinusitis. Otolaryngol Clin North Am 1997; 30: 331–9.
   PubMed Web of Science ®Google Scholar
• Brueggermann AB, Kugler KC, Doern CV, et al. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against S. pneu-moniae, H. influenzae, and M. catarrhalis. Antimicrob Agents Chemother 1997; 41: 1594–7.
   PubMed Web of Science ®Google Scholar
• Aldridge KE, Ashcraft D. Comparison of the in vitro activities of BAY 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob Agents Chemother 1997; 41: 709–11.
   PubMed Web of Science ®Google Scholar
• Burke T, Villanueva C, Mariano H, et al. Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis. Clin Therapeut 1999; 21: 1664–77.
   PubMed Web of Science ®Google Scholar
• Baz MN, Jannetti W, Villanueva C et al. The efficacy and tolerability of moxifloxacin compared to trovafloxacin in the treatment of acute sinusitis. Today's Therapeutic Trends 1999; 17: 303–19.
   Google Scholar
• Siegert R, Gehanno P, Nikolaidis P et al. A compari-son of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. Respir Med 2000; 94 (4): 337-44.
   Google Scholar
• Rakkar S, Roberts K, Towe BF et al. Moxifloxacin ver-sus amoxicillin clavulanate in the treatment of acute maxillary sinusitis: a primary care experience. Int J Clin Pract 2001; 55 (5): 309–15.
   PubMed Web of Science ®Google Scholar
• Arrieta J, Galgano E, Sakano X et al. Safety and effi-cacy of moxifloxacin versus amoxicillin clavulanate in the treat-ment of acute sinusitis. Presented at the 11th European Congress of Clinical Microbiology and Infectious Diseases, Istanbul, Turkey. 1-4 April 2001. Abstract # P865.
   Google Scholar
• Klossek JM and the sinusitis study group. Moxifloxacin versus trovafloxacin in the treatment of acute sinusitis. Presented at the 3rd European Congress of Chemotherapy, Madrid, Spain. 7-10 May 2000. Abstract # M178.
   Google Scholar
• Corcoran G, RoseIli A, Haverstock D, et al. The effica-cy of moxifloxacin compared to levofloxacin and amoxicillin clavulanate in reducing “practice time use” for the treatment of acute bacterial sinusitis. Pharmacotherapy 2001; 21 (3).
   Web of Science ®Google Scholar
• Pallares R. Treatment of pneumococcal pneumonia. Semin Respir Infect 1999; 14: 276–84.
   PubMedGoogle Scholar
• Niederman MS, Mandell L, Anzueto A et al. Guidelines for the management of adults with community-acquired pneu-monia. Diagnosis, assessment of severity, antimicrobial thera-py, and prevention. Am J Respir Crit Care Med 2001; 163: 1730–54.
   Google Scholar
• Patel T, Pearl J, Williams J, et al. Efficacy and safety of 10-day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Respir Med 2000; 94: 97–105.
   Google Scholar
• Fogarty C, Grossman C, Williams J, et al. Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia. Infect Med 1999; 16: 748–63.
   Google Scholar
• Hoffken G, Meyer H, Winter J, et al. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneu-monia. Respir Med 2001; 95: 553–64.
   Google Scholar
• Petitprez P, Arvis P, Marel M, et al. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moder-ate community-acquired suspected pneumococcal pneumonia in adults. Chest 2001; 119: 185–95.
   PubMed Web of Science ®Google Scholar
• Landen H, Bauer T. Efficacy, onset of action, and tol-erability of moxifloxacin in patients with community-acquired pneumonia. Clin Drug Invest 2001; 21 (12): 801–11.
   Web of Science ®Google Scholar
• Finch R, Collins O, Kubin R, et al. Moxifloxacin IV/P0 compared with amoxicillin/clavulanate IV/P0 with or without clarithromycin in the treatment of community-acquired pneu-monia. Clin Microbiol Infect 2001; 7 (Suppl 1): 167.
   PubMed Web of Science ®Google Scholar
• File T, Larsen L, Fogarty C, et al. Efficacy and safety of sequential (IV/PO) moxifloxacin for the treatment of com-munity-acquired pneumonia in hospitalised patients. Today's Therapeutic Trends 2001; 19 (4): 251–270.
   Google Scholar